Eidos Therapeutics, Inc.
Underestimation
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| P/E |
0/10
|
0 | -274.25 | -100% | -29.2 | -100% |
| P/S |
|
36595.5 | 56.99 | 64116.79% |
|
|
| P/BV |
|
38.7 | 256.7 | -84.92% |
|
|
| P/FCF |
|
-55.23 | -196.64 | -71.91% |
|
|
| Ev/Ebitda |
|
-49.6 | 12.51 | -496.48% |
|
|
| Ev/S |
|
0.0381 | 468.02 | -99.99% |
|
|
| Ev/FCF |
|
-56.28 | -237.28 | -76.28% |
|
|
| E/P |
|
-0.0213 | 0.0224 | -195.24% |
|
|
Efficiency
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Ebitda margin |
0/10
|
-0.0787 | -341.3 | -99.98% | -0.0525 | +50% |
| ROE |
|
-70.31 | 103.63 | -167.84% |
|
|
| ROA |
|
-59.27 | -2.84 | 1988.39% |
|
|
| ROIC |
|
-62.91 | 1.17 | -5458.86% |
|
|
| ROS |
|
-0.0795 | -298.77 | -99.97% |
|
|
| ROCE |
|
0 | 3.3 | -100% |
|
|
Debt
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Debt/Ebitda |
10/10
|
-0.2 | 0.9675 | -120.67% | -0.2 | 0% |
| Nеt Debt/Ebitda |
|
0 | 1.05 | -100% |
|
|
| Debt/Ratio |
|
0 | 0.179 | -100% |
|
|
| Debt/Equity |
|
0 | 1.58 | -100% |
|
|
| Debt/Net Income |
|
-0.198 | -1.51 | -86.88% |
|
|
Dividends
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Dividend yield |
0/10
|
0 | 0.5339 | -100% | 0 | 0% |
| Number of years of dividend growth |
|
0 | 0.8444 | -100% | ||
| DSI |
|
0 | 0.2147 | -100% |
|
|
| Average dividend growth |
|
0 | 1.27 | -100% |
|
|
| Average percentage for 5 years |
|
0 | 0.5087 | -100% |
|
|
| Average percentage for payments |
|
0 | 59.63 | -100% |
|
|
| Difference from average difference in sector |
|
-0.5339 |
Growth impulse
| Parameter | Grade | Value | Sector average | Difference with sector, % | ||
|---|---|---|---|---|---|---|
| Growth impulse Revenue in 5 years |
10/10
|
470270.37 | -90.69 | -518647.11% | ||
| Growth impulse Ebitda in 5 years |
|
0 | -111.17 | -100% | ||
| Growth impulse Net Income in 5 years |
|
3233.33 | -103.34 | -3228.83% | ||
| Growth impulse FCF in 5 years |
|
1500 | -114.74 | -1407.3% | ||
| Growth impulse EPS in 5 years |
|
1938.46 | -98.04 | -2077.21% |
IP Score
4/10
